Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Bystolic
Synonyms :
Class :
Cardioselective beta blockers
Brand Name :
Bystolic
Synonyms :
Class :
Cardioselective beta blockers
Dosage Forms & StrengthsÂ
Oral tablet/capsule:Â
2.5mg,5mg,10mg,20mgÂ
5
mg
Tablet
Orally 
every day
2
weeks
Do not exceed 40 mg/day
Dose Adjustments
Renal impairment: CrCl >30-80 mL/min: No dose adjustment provided CrCl <30 mL/min: 2.5 mg/day orally
Safety and efficacy not establishedÂ
Dosage Forms & StrengthsÂ
Oral tablet/capsule:Â
2.5mg,5mg,10mg,20mgÂ
5
mg
Tablet
Orally 
every day
2
weeks
Do not exceed 40mg/day
<70 years: Not established
>70years: 1.25mg/day orally, increase up to 2.5mg/day every 1-2 weeks. Do not exceed 10mg/day.
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
patiromer: they may diminish the serum concentration of nebivolol
may enhance the anti-hypertensive effect when both drugs are combined
may enhance the anti-hypertensive effect when both drugs are combined
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
may enhance the anti-hypertensive effect when both drugs are combined
may enhance the anti-hypertensive effect when both drugs are combined
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may enhance the anti-hypertensive effect when both drugs are combined
may increase toxicity of each other by unspecified interaction mechanism
it increases the effect of bradycardia of Beta-Blockers
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
may enhance the orthostatic hypotensive effect of alpha1-blockers
bunazosin (Not available in the United States)
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
it enhances the serum potassium levels
May enhances the effects of the other by pharmacodynamic synergism
It enhances the anti-hypertensive channel blocking when combined
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
it enhances the serum potassium levels
may decrease the levels of each other by increasing the metabolism
may decrease effects by unspecified interaction mechanism
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
it enhances the serum potassium levels
may decrease the serum potassium levels
It enhances the anti-hypertensive channel blocking when combined
may decrease serum potassium levels
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may decrease the serum potassium levels
it enhances the serum potassium levels
May enhances the effects of the other by pharmacodynamic synergism
May diminish the effects by pharmacodynamic antagonism
May enhances the effects of the other by pharmacodynamic synergism
it enhances the serum potassium levels
It enhances the anti-hypertensive channel blocking when combined
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
May enhances the effects of the other by pharmacodynamic synergism
it enhances the serum potassium levels
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
May enhances the effects of the other by pharmacodynamic synergism
CYP2D6 Inhibitors: they may enhance the serum concentration of nebivolol
CYP2D6 Inhibitors: they may enhance the serum concentration of nebivolol
CYP2D6 Inhibitors: they may enhance the serum concentration of nebivolol
CYP2D6 Inhibitors: they may enhance the serum concentration of nebivolol
CYP2D6 Inhibitors: they may enhance the serum concentration of nebivolol
fedratinib increases the effect of nebivolol by altering the intestinal/ hepatic CYP2D6 enzyme metabolism
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
it may enhance the serum potassium levels
glycopyrrolate inhaled and formoterolÂ
it decreases the serum potassium levels
Beta-blockers increase the concentration of bupivacaine in the serum
Beta-Blockers increase the effect of hypertension on epinephrine
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
may increase unspecified interaction mechanism
May enhances the effects of the other by pharmacodynamic synergism
may increase the levels of each other by decreasing the metabolism
May enhances the effects of the other by pharmacodynamic synergism
May diminish the effects by pharmacodynamic antagonism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
Frequency defined:Â Â
1-10%Â
Headache (6-9%)Â
Fatigue (2-5%)Â
Diarrhea (2-3%)Â
Nausea (1-3%)Â
Increased triglyceride levels and insulin resistance, decreased high-density lipoprotein (HDL) levels (1%)Â
Insomnia (1%)Â
Peripheral edema (1%)Â
Weakness (1%)Â
<1%Â
BradycardiaÂ
Chest painÂ
DyspneaÂ
Contraindicated in conditions such asÂ
HypersensitivityÂ
Cardiogenic shockÂ
BradychardiaÂ
Severe hepatic impairmentÂ
Pregnancy consideration:Â Â
Not recommended to use in pregnancyÂ
Pregnancy category: CÂ Â
Lactation: The excretion of the drug into the breast milk is not known; not recommended Â
Pregnancy category:Â
Â
Patient information leafletÂ
Generic Name: nebivololÂ
Pronounced: [ ne-BIV-oh-lol] Â
Why do we use nebivolol?Â
Nebivolol belongs to cardio-selective beta blockers, which is used to treat high blood pressure(hypertension)Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
